
|Articles|March 15, 2002
InSite obtains rights to optineurin gene
A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5













































.png)


